Anna T. Riegel

6.0k total citations · 1 hit paper
110 papers, 4.8k citations indexed

About

Anna T. Riegel is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Anna T. Riegel has authored 110 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Molecular Biology, 37 papers in Oncology and 34 papers in Genetics. Recurrent topics in Anna T. Riegel's work include Estrogen and related hormone effects (31 papers), Fibroblast Growth Factor Research (25 papers) and Cancer Cells and Metastasis (13 papers). Anna T. Riegel is often cited by papers focused on Estrogen and related hormone effects (31 papers), Fibroblast Growth Factor Research (25 papers) and Cancer Cells and Metastasis (13 papers). Anna T. Riegel collaborates with scholars based in United States, Germany and Saudi Arabia. Anna T. Riegel's co-authors include Anton Wellstein, Gordon L. Hager, Michael G. Cordingley, Ronald Reiter, Gerald E. Stoica, Heinz-Joachim List, Angera H. Kuo, Frank Czubayko, Emma T. Bowden and Bassem R. Haddad and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Anna T. Riegel

107 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells

2011 554 citations Xuefeng Liu, Virginie Ory et al. profile →

Peers

Countries citing papers authored by Anna T. Riegel

Since Specialization

Citations

This map shows the geographic impact of Anna T. Riegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna T. Riegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna T. Riegel more than expected).

Fields of papers citing papers by Anna T. Riegel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna T. Riegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna T. Riegel. The network helps show where Anna T. Riegel may publish in the future.

Co-authorship network of co-authors of Anna T. Riegel

This figure shows the co-authorship network connecting the top 25 collaborators of Anna T. Riegel. A scholar is included among the top collaborators of Anna T. Riegel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna T. Riegel. Anna T. Riegel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting TEAD in cancer 2025 ·Frontiers in Oncology ·(unknown), (unknown), Anton Wellstein, Anna T. Riegel, (unknown)	0
2	Circulating cell-free methylated DNA reveals tissue-specific, cellular damage from radiation treatment 2023 ·JCI Insight ·(unknown), Netanel Loyfer, (unknown), Marcel O. Schmidt, (unknown), Sidharth Jain, Sarah Martinez, (unknown), (unknown), (unknown), (unknown), Heng‐Hong Li, Anne Deslattes Mays, Sonali Rudra, Anna T. Riegel, Keith Unger, Tommy Kaplan, Anton Wellstein	6
3	Loss of ANCO1 Expression Regulates Chromatin Accessibility and Drives Progression of Early-Stage Triple-Negative Breast Cancer 2023 ·International Journal of Molecular Sciences ·Meng Yuan, (unknown), (unknown), Moray J. Campbell, Jan Blancato, (unknown), Marcel O. Schmidt, (unknown), Hong‐Bin Fang, Anton Wellstein, Anna T. Riegel, (unknown)	3
4	AIB1 is a novel target of the high‐risk HPV E6 protein and a biomarker of cervical cancer progression 2022 ·Journal of Medical Virology ·(unknown), Aleksandra Dakic, Megan E. Spurgeon, (unknown), Bhaskar Kallakury, Bo Zhao, Junran Zhang, Jian Zhu, Qin Ma, Ying Xu, Paul F. Lambert, Richard Schlegel, Anna T. Riegel, Xuefeng Liu	7
5	An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer 2021 ·Cancer Research ·(unknown), Moray J. Campbell, (unknown), Surojeet Sengupta, Garrett T. Graham, (unknown), (unknown), Marcel O. Schmidt, Gray W. Pearson, Olivier Loudig, Susan Fineberg, Anton Wellstein, Anna T. Riegel	10
6	ΔNp63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leader–Follower Relationship That Drives Collective Invasion 2020 ·Cancer Research ·Jill M. Westcott, (unknown), (unknown), (unknown), (unknown), Tuyen T. Dang, Anna T. Riegel, Rolf A. Brekken, Gray W. Pearson	12
7	An evaluation of palbociclib as a breast cancer treatment option: a current update 2020 ·Expert Opinion on Pharmacotherapy ·(unknown), (unknown), Anna T. Riegel, Paula R. Pohlmann	4
8	Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer 2019 ·Molecular Cancer Therapeutics ·(unknown), Garrett T. Graham, Virginie Ory, (unknown), (unknown), (unknown), Bhaskar Kallakury, Anton Wellstein, Anna T. Riegel	7
9	Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression 2019 ·EMBO Reports ·(unknown), Virginie Ory, Garrett T. Graham, (unknown), (unknown), (unknown), Meng Yuan, Marcel O. Schmidt, Anton Wellstein, Anna T. Riegel	16
10	Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism 2018 ·Scientific Reports ·E. ̃Tassi, (unknown), Marcel O. Schmidt, Xiaoting Ma, Khaled W. Kabbara, Aykut Üren, York Tomita, Regina Goetz, Moosa Mohammadi, Christopher S. Wilcox, Anna T. Riegel, Mattias Carlström, Anton Wellstein	10
11	The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ 2018 ·Breast Cancer Research and Treatment ·Virginie Ory, (unknown), (unknown), Bhaskar Kallakury, Anton Wellstein, Priscilla A. Furth, Anna T. Riegel	17
12	Conditionally Reprogrammed Normal and Transformed Mouse Mammary Epithelial Cells Display a Progenitor-Cell–Like Phenotype 2014 ·PLoS ONE ·(unknown), Virginie Ory, (unknown), Sonia Rosenfield, Mary Furlong, Luciane R. Cavalli, Michael D. Johnson, Xuefeng Liu, Richard Schlegel, Anton Wellstein, Anna T. Riegel	25
13	Tissue and Serum microRNAs in the KrasG12D Transgenic Animal Model and in Patients with Pancreatic Cancer 2011 ·PLoS ONE ·(unknown), Narayan Shivapurkar, Anju Preet, Anne Deslattes Mays, Ivana Peran, Sung Eun Kim, John L. Marshall, Anna T. Riegel, Anton Wellstein	72
14	Proteomic Analysis of Pathways Involved in Estrogen-Induced Growth and Apoptosis of Breast Cancer Cells 2011 ·PLoS ONE ·Zhang‐Zhi Hu, Benjamin L. Kagan, Eric A. Ariazi, Dean S. Rosenthal, Lihua Zhang, (unknown), Hongzhan Huang, Cathy Wu, V. Craig Jordan, Anna T. Riegel, Anton Wellstein	25
15	The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for Neu (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice 2008 ·Cancer Research ·Mark Fereshteh, Maddalena T. Tilli, Sung Eun Kim, Jianming Xu, Bert W. O’Malley, Anton Wellstein, Priscilla A. Furth, Anna T. Riegel	82
16	Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1 2007 ·Cancer Research ·Tyler Lahusen, Mark Fereshteh, Annabell S. Oh, Anton Wellstein, Anna T. Riegel	55
17	Recruitment of insulin receptor substrate-1 and activation of NF-κB essential for midkine growth signaling through anaplastic lymphoma kinase 2006 ·Oncogene ·Angera H. Kuo, Gerald E. Stoica, Anna T. Riegel, Anton Wellstein	47
18	Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors 2005 ·Laboratory Investigation ·Kevin McDonnell, Emma T. Bowden, (unknown), Becky Hoxter, Anna T. Riegel, Anton Wellstein	19
19	Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Δ3 on estrogenic ligands with different intrinsic activity 2003 ·Oncogene ·Ronald Reiter, Annabell S. Oh, Anton Wellstein, Anna T. Riegel	39
20	Comparison of Chromatin Remodeling and Transcriptional Activation of the Mouse Mammary Tumor Virus Promoter by the Androgen and Glucocorticoid Receptor 1999 ·Experimental Cell Research ·Heinz-Joachim List, (unknown), Jianming Lü, Mark Danielsen, Anton Wellstein, Anna T. Riegel	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact